OR WAIT null SECS
© 2023 MJH Life Sciences and Consultant Live. All rights reserved.
On the HCPLive gout page, resources on the topics of medical news and expert insight into gouty arthritis can be found. Content includes articles, interviews, videos, podcasts, and breaking news on gout, and more.
March 24, 2023
SEL-212, an alternative to standard therapy that is administered once monthly, has proven to be particularly helpful for patients with severe gout, a historically underserved population.
March 21, 2023
An announcement from Selecta Biosciences and Sobi provide the latest update on DISSOLVE clinical program, with new data indicating SEL-212 met the primary endpoint of achieving serum urate control during month 6.
March 09, 2023
Dialysis-dependent patients in the US with gout have an increased risk of cardiovascular comorbidities, hospitalization, and mortality. Results emphasize the need for improved treatments to enhance outcomes for this patient population.
March 08, 2023
An international pilot study shows a probiotic candidate may improve both management of gout and relevant blood serum levels in treated patients.
March 03, 2023
A brief increase in venous thromboembolism (VTE) was reported within 30 days after a hospitalization or primary care visit for gout flare. The highest incidence occurred during the 16-30 day period after the flare.
February 24, 2023
Investigators evaluated the link between gout and thalassemia using data from Taiwan's Longitudinal Health Insurance Database 2000 (LHID 2000).
February 22, 2023
Of the 23 biomarkers identified in patients with gouty arthritis and hyperuricemia, kynurenic acid, thymine, and phosphatidylinositol (PI) differed from previous gout research.
Patients' perceptions of the effectiveness and necessity of allopurinol for gout treatment proved to be strong factors influencing intentional adherence.
Ginger Hultin, MS, RDN, explained the benefits of an anti-inflammatory nutrition plan for patients living with rheumatic and autoimmune conditions, as well as what rheumatologists need to know.
An analysis of the DELIVER and DAPA-HF trials provides an overview of the impact of gout on heart failure outcomes and effects of dapagliflozin in this patient population.